Cytek Biosciences Inc. Common Stock Q3 2026 Earnings Recap

Cytek shares fell 8.2% after earnings, with the modest 2% revenue growth and sharp year-over-year decline in APAC likely weighing on the reaction. U.S. growth and strength in high-end instruments were offset by continued weakness in APAC and a full-year outlook that is not included in the available transcript.

Key Takeaways

• Q3 revenue was $53.2 million, up 2% year-over-year.
• U.S. revenue increased 12% to $30.4 million; EMEA was up 1% to $12.5 million. APAC revenue was $8.3 million, down 25% year-over-year despite rising 5% sequentially.
• Combined Aurora and Aurora EVO placements grew 23% year-over-year, with EVO placements nearly doubling; high-end full-spectrum profiling instrument revenue rose 11%.
• Service and reagent revenue totaled $19.1 million, or 36% of last 12 months’ revenue, versus 33% a year earlier.
• Cytek added 140 instruments in the quarter, bringing its installed base to 4,073; the company plans a broader commercial launch of Borealis in fiscal 2027.